Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2018
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation predominant, diarrhea predominant, and mixed. Our analysis focuses on IBS-D, the diarrhea predominant subtype. Limited treatment options are currently available for IBS and only a few drugs have secured an FDA approval for IBS-D. Treatment options include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), a 5-HTR modulator (Sebela Pharmaceuticals’ Lotronex), and two recently approved agents: Salix Pharmaceuticals’ Xifaxan, an antibiotic, and Allergan’s Viberzi, an opioid delta receptor antagonist.
Questions Answered
What is the patient share of key therapies and brands by line of therapy in newly diagnosed IBS-D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-D patients?
How have Xifaxan and Viberzi been integrated into the treatment algorithm?
What percentage of IBS-D patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
What percentage of IBS-D patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
What are the product-level compliance and persistency rates among drug-treated patients with IBS-D?
Product Description
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.